The following is a summary of the Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Vaxart reported Q1 2024 revenue of $2.2 million, primarily from revenue recognized under BARDA contract and non-cash royalty revenue from Inavir sales in Japan.

• The company ended the first quarter with cash, cash equivalents, and investments amounting to $36.7 million.

Business Progress:

• Positive results from Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate in lactating mothers.

• Vaxart plans to discuss the progress of their norovirus program with the FDA in mid-2024.

• Vaxart is preparing to initiate a Phase 2b trial for their COVID-19 vaccine candidate XBB as early as Q2 2024, pending additional funds and regulatory alignment.

• The company is set to accelerate investment in their vaccine pipeline owing to promising preclinical data from their COVID-19 XBB construct.

• A meeting with the FDA to review clinical findings and inform future regulatory pathway and clinical steps is planned for mid-2024.

• Vaxart has enough vaccine material produced for the upcoming Phase 2b COVID study.

• Vaxart considers their oral pill vaccine technology to be a potential tool against vaccine hesitancy.

• The company continues promoting its vaccine benefits to the medical community.

More details: Vaxart IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.